Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olesoxime - Roche

Drug Profile

Olesoxime - Roche

Alternative Names: Cholest-4-en-3-one,-oxime; Cholest-4-en-3-ylidenehydroxylamine; RG-6083; TRO-19622

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trophos
  • Developer Roche; Trophos
  • Class Analgesics; Cholestenones; Hepatoprotectants; Neuroprotectants; Oximes; Small molecules
  • Mechanism of Action Mitochondrial permeability transition pore modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Diabetic neuropathies; Huntington's disease; Multiple sclerosis; Neuropathic pain; Non-alcoholic steatohepatitis; Spinal muscular atrophy

Most Recent Events

  • 26 Jul 2018 Discontinued - Phase-II/III for Spinal muscular atrophy (In adolescents, In children, In adults) in Poland, France, Netherlands, Germany (PO) (Roche pipeline, July 2018)
  • 26 Jul 2018 Discontinued - Phase-II for Multiple sclerosis in France (PO) (Roche pipeline, July 2018)
  • 26 Jul 2018 Discontinued - Phase-II/III for Spinal muscular atrophy (In adolescents, In children, In adults) in Belgium (PO) (Roche pipeline, July 2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top